ReoPro Post-Approval Trials Have Cost $250 Mil. Including J&J Stent Work

Centocor has spent about $250 mil. on post-approval trials since 1995 to demonstrate the efficacy of ReoPro in combination with coronary stents and to generate outcomes data for the antiplatelet monoclonal, Centocor CEO David Holveck reported at the recent Wharton New Ventures in Health Care Conference.